Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Crossing over

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Crossing over. Displaying page 1 of 1.
    EudraCT Number: 2016-005189-75 Sponsor Protocol Number: BO39633 Start Date*: 2017-07-13
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL, MULTICENTER EXTENSION AND LONG-TERM OBSERVATIONAL STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH- AND/OR F. HOFFMANN LA ROCHE LTD-SPONSORED ATEZOLIZUMAB STUDY
    Medical condition: Cancer (Future parent protocols may include other cancer that are not included in this section)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046721 Urothelial carcinoma bladder stage III LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029514 Non-small cell lung cancer NOS LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Trial now transitioned) BE (Completed) FR (Trial now transitioned) NL (Ongoing) SI (Completed) PT (Completed) DE (Completed) LV (Prematurely Ended) LT (Ongoing) SK (Prematurely Ended) BG (Completed) IT (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004101-40 Sponsor Protocol Number: OS440-3005 Start Date*: 2018-03-23
    Sponsor Name:Osmotica Pharmaceutical US LLC
    Full Title: An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients with Spasticity (Study OS440-3005).
    Medical condition: Spasticity in patients with multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2020-001055-40 Sponsor Protocol Number: 111-209 Start Date*: 2020-07-29
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A randomized, controlled, open-label clinical trial with an open-label extension to investigate the safety of BMN 111 in infants and young children with achondroplasia at risk of requiring cervicom...
    Medical condition: achondroplasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10000452 Achondroplasia LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-018401-10 Sponsor Protocol Number: 156-08-271 Start Date*: 2010-07-07
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc
    Full Title: A Multi-center, Open-label, Extension Study to Evaluate the Long-term Efficacy and Safety of Oral Tolvaptan Tablet Regimens in Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) BE (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003570-26 Sponsor Protocol Number: CLN-PRO-V011 Start Date*: 2019-09-07
    Sponsor Name:Humacyte, Inc.
    Full Title: A Phase 2 Assessment of Humacyte’s Human Acellular Vessel in Patients Needing Vascular Access for Dialysis
    Medical condition: End-stage renal disease (ESRD) requiring placement of an arteriovenous (AV) graft in the arm (upper- or forearm) for dialysis access.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10042613 Surgical and medical procedures SOC
    21.1 10042613 - Surgical and medical procedures 10066772 Vascular access operation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003180-35 Sponsor Protocol Number: R04725 Start Date*: 2018-06-15
    Sponsor Name:Manchester University NHS Foundation Trust
    Full Title: Feasibility study on the effects of postnatal enalapril on maternal cardiovascular function following preterm pre-eclampsia
    Medical condition: Postnatal (PN) cardiovascular dysfunction following preterm pre-eclampsia (pPE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10036485 Pre-eclampsia PT
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10036485 Pre-eclampsia PT
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10040444 Severe pre-eclampsia LLT
    20.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2012-004295-19 Sponsor Protocol Number: 1209-EnTF Start Date*: 2014-10-08
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line t...
    Medical condition: Histologically confirmed differentiated or medullary thyroid cancer by local pathologist.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033701 Papillary thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) GB (Completed) NL (Completed) DK (Completed) FR (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002233-37 Sponsor Protocol Number: IPX203-B16-02 Start Date*: 2019-03-18
    Sponsor Name:Impax Laboratories, LLC
    Full Title: A randomized controlled study to compare the safety and efficacy of IPX203 with immediate-release carbidopa-levodopa in Parkinson's disease patients with motor fluctuations.
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    20.0 10029205 - Nervous system disorders 10028035 Movement disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002258-23 Sponsor Protocol Number: C0701a/204/ON/US Start Date*: 2005-11-07
    Sponsor Name:Cephalon Inc.
    Full Title: A Randomized, Open Label Study of Oral CEP 701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT 3 Activating Mutations.Estud...
    Medical condition: Relapsed Acute Myeloid Leukaemia (AML) expressing FLT-3 activating mutations.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Prematurely Ended) SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000522-18 Sponsor Protocol Number: 2016-01 Start Date*: Information not available in EudraCT
    Sponsor Name:PIBDNet
    Full Title: Risk stratified randomized controlled trial in paediatric Crohn’s Disease: Methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or at high risk for aggressive...
    Medical condition: Crohn’s disease
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) BE (Completed) PL (Ongoing) CZ (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004536-37 Sponsor Protocol Number: SHAPE Start Date*: 2020-10-19
    Sponsor Name:Leipzig University
    Full Title: Treatment of MDS/AML patients with an impending hematological relapse with azacitidine alone or in combination with pevonedistat - a randomized phase 2 trial
    Medical condition: Acute myeloid leukemia (AML) and Myelodysplastic syndromes (MDS) with impending hematological relapse
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006017-34 Sponsor Protocol Number: CBYL719X2104 Start Date*: 2013-03-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase Ib dose escalation/randomized phase II, multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma
    Medical condition: Head and Neck Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-001161-41 Sponsor Protocol Number: BRF113928 Start Date*: 2012-09-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-smal...
    Medical condition: Advanced non-small cell lung cancer and BRAF mutations
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NO (Completed) DE (Completed) ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001178-41 Sponsor Protocol Number: TPI-ALV-201 Start Date*: 2017-10-10
    Sponsor Name:Tolero Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with an Exploratory Arm in Patients with Newly Diagnosed High-Risk AML a...
    Medical condition: Relapsed/Refractory Acute Myeloid Leukemia (AML) with MCL-1 dependence of ≥40% demonstrated by mitochondrial profiling. Newly diagnosed high-risk (NDHR) AML with MCL-1 dependence of ≥ 40% demonst...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10060558 Acute myeloid leukemia recurrent LLT
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    20.0 100000004864 10000887 Acute myeloid leukemia in remission LLT
    20.0 100000004864 10054294 Acute myeloid leukemia (in remission) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001430-16 Sponsor Protocol Number: 3066K1-305-WW Start Date*: 2005-04-20
    Sponsor Name:Wyeth Research, Division of Wyeth Pharmaceuticals, Inc. Clinical Research and Development
    Full Title: An Open-label, Randomized, Phase 3 Trial of intravenous Temsirolimus (CCI-779) at two Dose Levels Compared to Investigator's Choice Therapy in relapsed, Refractory Subjects with Mantle Cell lymphom...
    Medical condition: Mantle Cell Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) SE (Completed) GB (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-000359-15 Sponsor Protocol Number: DZB-CS-201 Start Date*: 2020-02-11
    Sponsor Name:Basilea Pharmaceutica International Ltd.
    Full Title: An open-label multi-cohort Phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations (FIDES-02)
    Medical condition: urothelial cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10077840 Urothelial cancer of renal pelvis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000555-42 Sponsor Protocol Number: HMR1726D/3001 Start Date*: 2004-11-22
    Sponsor Name:Sanofi-aventis US, Inc
    Full Title: A randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the ac...
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed) AT (Completed) IT (Completed) GB (Completed) PT (Completed) CZ (Completed) EE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-000032-28 Sponsor Protocol Number: LAL-CL03 Start Date*: 2011-04-18
    Sponsor Name:Synageva Biopharma Corp.
    Full Title: An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 in Children with Growth Failure Due to Lysosomal ...
    Medical condition: Growth failure in children due to lysosomal acid lipase deficiency (Wolman disease).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    14.1 10027433 - Metabolism and nutrition disorders 10021605 Inborn errors of metabolism HLGT
    14.1 10010331 - Congenital, familial and genetic disorders 10024579 Lysosomal storage disorders HLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) DE (Prematurely Ended) IT (Completed) IE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 20:43:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA